Bahuguna Pankaj, Baker Peter Alan, Briggs Andrew, Gulliver Sophie, Hesselgreaves Hannah, Mehndiratta Abha, Ruiz Francis, Tyagi Kirti, Wu Olivia, Guzman Javier, Grieve Eleanor
School of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, Health Economics and Health Technology Assessment, University of Glasgow, Glasgow, UK.
Global Health Policy Program, Center for Global Development, London, UK.
BMJ Evid Based Med. 2025 Mar 20. doi: 10.1136/bmjebm-2023-112487.
An increasing investment in health technology assessment (HTA) in low-income and middle-income countries has generated greater interest from policy-makers about the value and return on investment (ROI) of HTA. Few studies have, however, quantified the benefits of HTA in terms of its value to the health system. This evaluation aims to quantify the impact and ROI achieved by the HTA agency in India (HTAIn).A framework developed by the University of Glasgow was used to review three 'hta's commissioned by HTAIn between 2018 and 2020, taking into account the opportunity cost of investing in these processes. Costs included fixed costs for HTAIn and costs for undertaking each 'hta'. Attributable benefits are calculated by subtracting the counterfactual (benefits that might have been realised without an HTA) from realised benefits.HTAIn sits under the Department of Health Research, Ministry of Health and Family Welfare, Government of India. It was set up to facilitate the process of transparent and evidence-informed decision-making in healthcare in India.HTA helps decision-makers to understand the consequences of alternative courses of action and to select the options that produce the best outcomes at the lowest cost. Institutionalisation of HTA is seen as pivotal to supporting universal health coverage as a means of supporting a better allocation of finite resources, cost containment and the maximisation of health.Net health benefits are our measure of value. The ROI of HTAIn is calculated by aggregating attributable benefits and offsetting them against the costs of investment.Our findings show that investing in HTAIn yields a return of 9:1, with potential to increase to 71:1 with full implementation of HTA recommendations. Variability of ROI ranged from 5:1 to 40:1 between the different interventions and diseases.While HTAIn requires financial investment, it is an efficient use of resources. The potential for greater impact and the variability of the ROI between interventions underline the importance of planning for implementation and good topic selection in HTA.
低收入和中等收入国家对卫生技术评估(HTA)的投资不断增加,这引发了政策制定者对HTA的价值和投资回报率(ROI)更大的兴趣。然而,很少有研究从HTA对卫生系统的价值方面量化其益处。本评估旨在量化印度卫生技术评估机构(HTAIn)所实现的影响和投资回报率。采用格拉斯哥大学开发的一个框架,对HTAIn在2018年至2020年间委托开展的三项“卫生技术评估”进行审查,同时考虑到投资于这些流程的机会成本。成本包括HTAIn的固定成本以及开展每项“卫生技术评估”的成本。可归因效益通过用实际效益减去反事实情况(即没有卫生技术评估可能实现的效益)来计算。
HTAIn隶属于印度政府卫生和家庭福利部卫生研究司。其设立目的是促进印度医疗保健领域透明且基于证据的决策过程。卫生技术评估有助于决策者理解不同行动方案的后果,并选择以最低成本产生最佳结果的选项。卫生技术评估的制度化被视为支持全民健康覆盖的关键,全民健康覆盖是支持更合理分配有限资源、控制成本和实现健康最大化的一种手段。
净健康效益是我们衡量价值的指标。HTAIn的投资回报率通过汇总可归因效益并将其与投资成本相抵消来计算。我们的研究结果表明,对HTAIn的投资产生了9:1的回报,若全面实施卫生技术评估建议,回报率有可能增至71:1。不同干预措施和疾病之间的投资回报率差异在5:1至40:1之间。
虽然HTAIn需要财政投资,但它是对资源的有效利用。更大影响的潜力以及不同干预措施之间投资回报率的差异凸显了在卫生技术评估中规划实施和选好主题的重要性。